Please provide your email address to receive an email when new articles are posted on . ATR-04 has received a fast track designation from the FDA for epidermal growth factor receptor ...
LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...
ATR04-484 is a live biotherapeutic product targeting EGFR inhibitor-associated rashes in cancer patients, containing a modified Staphylococcus epidermidis strain. EGFR inhibitors, used in treating ...
A research team from the UCLA Health Jonsson Comprehensive Cancer Center, the University of Texas MD Anderson Cancer Center, and collaborators have demonstrated that a novel topical BRAF inhibitor gel ...
Please provide your email address to receive an email when new articles are posted on . ATR-04 is currently being developed to treat dermal toxicity from epidermal growth factor receptor inhibitor ...
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...
Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life Acne-like skin rash is a common side effect from colorectal ...
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback